Compound 21, a selective agonist of angiotensin AT₂ receptors, prevents endothelial inflammation and leukocyte adhesion <i>in vitro</i> and <i>in vivo</i>

Abstract

C21 prevented TNFα-induced and HFD-induced vascular inflammation in vitro and in vivo. Our data provide strong evidence that the anti-atherosclerotic actions of C21 were due to vascular anti-inflammatory effects, mediated by AT2 receptors.